Eli Lilly and Company (BVMF:LILY34)

Market Cap	4.97T
Revenue (ttm)	316.67B
Net Income (ttm)	98.13B
Shares Out	n/a
EPS (ttm)	108.94
PE Ratio	50.60
Forward PE	32.62
Dividend	0.75 (0.41%)
Ex-Dividend Date	Nov 13, 2025

Volume	5,623
Average Volume	18,191
Open	185.08
Previous Close	185.08
Day's Range	183.00 - 187.48
52-Week Range	113.00 - 208.36
Beta	0.35
RSI	43.97
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: LILY34

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD